Clover Biopharmaceuticals, Inc.
B-A10 Room No.1, Mansion
Chengdu Hi-tech Zone Hi-tech Incubation Park
Tianhe Incubator, Nan Yan Xian Tian Fu Avenue
Chengdu
610041
China
Tel: 028-85336966
Fax: 028-85336933
Website: http://www.cloverbiopharma.com/
Email: jiang.pu@cloverbiopharma.com
About Clover Biopharmaceuticals, Inc.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
LEADERSHIP:
Founders: Peng Liang, Xiaodong Wang and Jianwei Zhu
CSO: Joshua Liang
COO: Zheng Ping
CIO: Pu Jiang
CLINICAL TRIAL:
93 articles with Clover Biopharmaceuticals, Inc.
-
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China
2/19/2023
Clover Biopharmaceuticals, Ltd. announced that it entered into an exclusive agreement with Adimmune Corporation for Clover to distribute AdimFlu-S in mainland China, where it is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older.
-
UPDATE -- Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
2/14/2023
Clover Biopharmaceuticals, Ltd. announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in the People’s Republic of China has begun with the first doses delivered and administered in Changxing, Zhejiang as part of China’s national second booster dose campaign targeting older adults, immunocompromised individuals and individuals with comorbidities.
-
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
2/14/2023
Clover Biopharmaceuticals, Ltd. announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in the People’s Republic of China has begun with the first doses delivered and administered in Changxing, Zhejiang as part of China’s national second booster dose campaign targeting older adults, immunocompromised individuals and individuals with comorbidities.
-
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
1/16/2023
Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, provided updates on the commercialization of SCB-2019 in China and strategic priorities in 2023.
-
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
11/30/2022
Clover Biopharmaceuticals, Ltd. and the International Vaccine Institute announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.
-
Pres. Joe Biden declared the COVID-19 pandemic over. Biopharma stocks react as vaccines and antivirals are still in development.
-
Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
9/20/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, announced that Clover’s contract development and manufacturing organization has received a European Union Good Manufacturing Practice certificate for the production of Clover’s lead COVID-19 vaccine candidate, SCB-2019.
-
Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
9/19/2022
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 (CpG 1018/Alum) as a universal COVID-19 booster vaccine candidate.
-
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
-
Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
9/5/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 as a universal COVID-19 booster vaccine candidate.
-
Global Roundup: Clover Progresses Universal COVID-19 Booster, TikoMed Proves Platform in ALS
9/1/2022
Clover's SCB-2019 showed a robust immune response to the Omicron BA.5 sub-variant, while BrainsWay, TikoMed and more provide updates on their businesses and pipelines. -
Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
8/29/2022
Clover Biopharmaceuticals, Ltd. announced positive Phase 2/3 clinical trial data demonstrating that its lead COVID-19 vaccine candidate, SCB-2019, elicited a robust immune response to Omicron BA.5 subvariant, the dominant SARS-CoV-2 variant circulating globally, building upon previously announced results for neutralization against Omicron BA.2 and BA.1.
-
Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
8/25/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from a global Phase 2/3 trial evaluating Clover's COVID-19 vaccine candidate, SCB-2019, in adolescents.
-
Clover Announces Executive Leadership Appointments
7/1/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced the appointments of Aileen Wang as Chief Financial Officer and Lily Yang as Chief People Officer.
-
Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover's homologous booster against Omicron increases antibodies, and much more.
-
The current vaccinations still offer significant protection against severe diseases. Meanwhile, vaccine companies are progressing in designing and testing Omicron-specific booster shots.
-
Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster
6/27/2022
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced new positive clinical data in individuals vaccinated with a third dose of SCB-2019 as a homologous booster against the Omicron variant.
-
Clover Appoints Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to Board of Directors
6/20/2022
Clover Biopharmaceuticals, Ltd. announced the appointment of Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to the company’s Board of Directors.
-
Clover dosed the first participants in a Phase III study of its COVID-19 booster shot, while Global Access Diagnostics, Orbit Discovery, Proximie and more provide business and pipeline updates.
-
Clover Doses First Patient with SCB-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia
6/14/2022
Clover Biopharmaceuticals, Ltd. announced that the first patient has been dosed with SCB-219M, an innovative thrombopoietin receptor agonist mimetic Fc-fusion protein, in a Phase 1 clinical trial to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and efficacy of SCB-219M in cancer patients with chemotherapy-induced thrombocytopenia.